Aerie Pharmaceuticals Inc (NASDAQ:AERI) CEO Vicente Anido, Jr. sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $62.01, for a total transaction of $3,100,500.00. Following the completion of the transaction, the chief executive officer now directly owns 176,320 shares of the company’s stock, valued at approximately $10,933,603.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Aerie Pharmaceuticals traded up $0.90, reaching $63.90, during trading hours on Thursday, Marketbeat reports. 6,665 shares of the company’s stock were exchanged, compared to its average volume of 355,562. The company has a market cap of $2.51 billion, a PE ratio of -18.99 and a beta of 0.94. The company has a current ratio of 13.57, a quick ratio of 13.53 and a debt-to-equity ratio of 0.52. Aerie Pharmaceuticals Inc has a fifty-two week low of $47.05 and a fifty-two week high of $66.60.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings results on Tuesday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.04. equities analysts forecast that Aerie Pharmaceuticals Inc will post -3.75 earnings per share for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Summit Trail Advisors LLC grew its holdings in shares of Aerie Pharmaceuticals by 12.1% during the first quarter. Summit Trail Advisors LLC now owns 11,922 shares of the company’s stock valued at $440,000 after buying an additional 1,283 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Aerie Pharmaceuticals during the first quarter valued at $942,000. Handelsbanken Fonder AB grew its holdings in shares of Aerie Pharmaceuticals by 100.0% during the first quarter. Handelsbanken Fonder AB now owns 260,000 shares of the company’s stock valued at $14,105,000 after buying an additional 130,000 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new stake in shares of Aerie Pharmaceuticals during the first quarter valued at $258,000. Finally, Royal Bank of Canada grew its holdings in shares of Aerie Pharmaceuticals by 8.3% during the first quarter. Royal Bank of Canada now owns 32,875 shares of the company’s stock valued at $1,784,000 after buying an additional 2,511 shares during the last quarter.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.